In collaboration with Oxford University, a small Phase 2a challenge study was conducted where volunteers were immunized with AMA1-C1/Alhydrogel+CPG 7909, followed by a challenge dose of erythrocytes infected with malaria parasites. A significant correlation was observed between parasite multiplication rate and both vaccine-induced growth-inhibitory activity and AMA1 antibody titers. However, this did not translate to an overall observable clinically relevant vaccine effect in these volunteers. Currently the collaboration with Oxford University continues in a prime-boost study where volunteers are primed with viral-vectored AMA1 vaccines followed by a booster dose of AMA1-C1/Alhydrogel+CPG 7909. The AMA1-C1/Aldhyrgel+CPG7909 is also being tested in combination with another merozoite stage antigen in an Aotus challenge model.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Duncan, Christopher J A; Hill, Adrian V S; Ellis, Ruth D (2012) Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother 8:706-14
Zhu, Daming; Huang, Shuhui; McClellan, Holly et al. (2012) Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer. Vaccine 30:189-94
Miura, Kazutoyo; Perera, Suwani; Brockley, Sarah et al. (2011) Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay. PLoS One 6:e20947
Zhu, Daming; McClellan, Holly; Dai, Weili et al. (2011) Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine. Vaccine 29:3640-5
Duncan, Christopher J A; Sheehy, Susanne H; Ewer, Katie J et al. (2011) Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One 6:e22271
Ellis, Ruth D; Sagara, Issaka; Doumbo, Ogobara et al. (2010) Blood stage vaccines for Plasmodium falciparum: Current status and the way forward. Hum Vaccin 6:
Ouattara, Amed; Mu, Jianbing; Takala-Harrison, Shannon et al. (2010) Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar J 9:175
Miura, Kazutoyo; Zhou, Hong; Diouf, Ababacar et al. (2009) Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16:963-8
Crompton, Peter D; Mircetic, Marko; Weiss, Greta et al. (2009) The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol 182:3318-26
Sagara, Issaka; Dicko, Alassane; Ellis, Ruth D et al. (2009) A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27:3090-8

Showing the most recent 10 out of 14 publications